|
1
|
Low SY, Tan BS, Choo HL, Tiong KH, Khoo AS
and Leong CO: Suppression of BCL-2 synergizes cisplatin sensitivity
in nasopharyngeal carcinoma cells. Cancer Lett. 314:166–175. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee AW, Lin JC and Ng WT: Current
management of nasopharyngeal cancer. Semin Radiat Oncol.
22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoshizaki T, Ito M, Murono S, Wakisaka N,
Kondo S and Endo K: Current understanding and management of
nasopharyngeal carcinoma. Auris Nasus Larynx. 39:137–144. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Orlandi E, Tomatis S, Potepan P, Bossi P,
Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C,
Locati L, et al: Critical analysis of locoregional failures
following intensity-modulated radiotherapy for nasopharyngeal
carcinoma. Future Oncol. 9:103–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bussink J, van der Kogel AJ and Kaanders
JH: Activation of the PI3-K/AKT pathway and implications for
radioresistance mechanisms in head and neck cancer. Lancet Oncol.
9:288–296. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimura T: Acquired radioresistance of
cancer and the AKT/GSK3β/cyclin D1 overexpression cycle. J Radiat
Res. 52:539–544. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Chen LH, Yuan YW, Li QS, Sun AM and
Guan J: Activation of AKT is associated with metastasis of
nasopharyngeal carcinoma. Tumour Biol. 33:241–245. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li HF, Kim JS and Waldman T:
Radiation-induced Akt activation modulates radioresistance in human
glioblastoma cells. Radiat Oncol. 4:432009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xia S, Zhao Y, Yu S and Zhang M: Activated
PI3K/Akt/COX-2 pathway induces resistance to radiation in human
cervical cancer HeLa cells. Cancer Biother Radiopharm. 25:317–323.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang HH, Lipovsky AI, Dibble CC, Sahin M
and Manning BD: S6K1 regulates GSK3 under conditions of
mTOR-dependent feedback inhibition of Akt. Mol Cell. 24:185–197.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albert JM, Kim KW, Cao C and Lu B:
Targeting the Akt/mammalian target of rapamycin pathway for
radiosensitization of breast cancer. Mol Cancer Ther. 5:1183–1189.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shinohara ET, Cao C, Niermann K, Mu Y,
Zeng F, Hallahan DE and Lu B: Enhanced radiation damage of tumor
vasculature by mTOR inhibitors. Oncogene. 24:5414–5422. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao C, Subhawong T, Albert JM, Kim KW,
Geng L, Sekhar KR, Gi YJ and Lu B: Inhibition of mammalian target
of rapamycin or apoptotic pathway induces autophagy and
radiosensitizes PTEN null prostate cancer cells. Cancer Res.
66:10040–10047. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nassim R, Mansure JJ, Chevalier S, Cury F
and Kassouf W: Combining mTOR inhibition with radiation improves
antitumor activity in bladder cancer cells in vitro and in vivo: A
novel strategy for treatment. PLoS One. 8:e652572013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Abraham RT and Wiederrecht GJ:
Immunopharmacology of rapamycin. Annu Rev Immunol. 14:483–510.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Prevo R, Deutsch E, Sampson O, Diplexcito
J, Cengel K, Harper J, O'Neill P, McKenna WG, Patel S and Bernhard
EJ: Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine
inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res.
68:5915–5923. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suárez C, Rodrigo JP, Rinaldo A,
Langendijk JA, Shaha AR and Ferlito A: Current treatment options
for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol.
267:1811–1824. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim MK, Kim TJ, Sung CO, Choi CH, Lee JW,
Kim BG and Bae DS: High expression of mTOR is associated with
radiation resistance in cervical cancer. J Gynecol Oncol.
21:181–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romano G: The role of the dysfunctional
akt-related pathway in cancer: Establishment and maintenance of a
malignant cell phenotype, resistance to therapy, and future
strategies for drug development. Scientifica (Cairo).
2013:3171862013.PubMed/NCBI
|
|
22
|
Liu SC, Tsang NM, Chiang WC, Chang KP,
Hsueh C, Liang Y, Juang JL, Chow KP and Chang YS: Leukemia
inhibitory factor promotes nasopharyngeal carcinoma progression and
radioresistance. J Clin Invest. 123:5269–5283. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chung J, Kuo CJ, Crabtree GR and Blenis J:
Rapamycin-FKBP specifically blocks growth-dependent activation of
and signaling by the 70 kd S6 protein kinases. Cell. 69:1227–1236.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Terada N, Takase K, Papst P, Nairn AC and
Gelfand EW: Rapamycin inhibits ribosomal protein synthesis and
induces G1 prolongation in mitogen-activated T lymphocytes. J
Immunol. 155:3418–3426. 1995.PubMed/NCBI
|
|
25
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jirawatnotai S, Hu Y, Michowski W, Elias
JE, Becks L, Bienvenu F, Zagozdzon A, Goswami T, Wang YE, Clark AB,
et al: A function for cyclin D1 in DNA repair uncovered by protein
interactome analyses in human cancers. Nature. 474:230–234. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shimura T, Fukumoto M and Kunugita N: The
role of cyclin D1 in response to long-term exposure to ionizing
radiation. Cell Cycle. 12:2738–2743. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fury MG, Lee NY, Sherman E, Ho AL, Rao S,
Heguy A, Shen R, Korte S, Lisa D, Ganly I, et al: A phase I study
of everolimus + weekly cisplatin + intensity modulated radiation
therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys.
87:479–486. 2013. View Article : Google Scholar : PubMed/NCBI
|
